TY - JOUR
T1 - Maintaining a clinical weight loss after intensive lifestyle intervention is the key to cardiometabolic health
AU - Jørgensen, Sune Dandanell
AU - Skovborg, Camilla
AU - Præst, Charlotte Boslev
AU - Kristensen, Kasper Bøgh
AU - Nielsen, Malene Glerup
AU - Lionett, Sofie
AU - Jørgensen, Sofie Drevsholt
AU - Vigelsø Hansen, Andreas
AU - Dela, Flemming
AU - Helge, Jørn Wulff
N1 - Copyright © 2016 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.
PY - 2017/7
Y1 - 2017/7
N2 - Objective Intensive lifestyle interventions (ILI) are criticised for ineffective obesity treatment because weight loss over time is modest and thus of limited clinical relevance. However, a subgroup (5–30%) maintains a clinical weight loss >10%, but it is not clear if cardiometabolic health follows this pattern. The aim was to study the effect of different magnitudes of weight loss maintenance after ILI on cardiometabolic health. Methods Eighty out of 2420 former participants (age: 36 ± 1, BMI: 38 ± 1, (means ±SE)) in an 11–12-week ILI were recruited into 3 groups; clinical weight loss maintenance (>10% weight loss), moderate maintenance (1–10%), and weight regain based on weight loss at follow-up (5.3 ± 0.4 years). Weight loss during the ILI was achieved by increased physical activity and hypo-caloric diet. Dual X-ray Absorptiometry, blood sample, skeletal muscle biopsy and VO2max test were used to determine cardiometabolic health at follow-up. Results At follow-up, the clinical weight loss maintenance group scored better in the following variables compared to the other groups: BMI (31 ± 1, 33 ± 2, 43 ± 2 kg/m2), composition (34 ± 2, 40 ± 1, 49 ± 1% fat), visceral adipose tissue (0.8 ± 0.2, 1.7 ± 0.5, 2.4 ± 0.4 kg), plasma triglycerides (0.8 ± 0.2, 1.3 ± 0.4, 1.6 ± 0.3 mmol/L), plasma glucose (4.9 ± 0.1, 5.9 ± 0.4, 5.9 ± 0.1 mmol/L), Hb1Ac (5.1 ± 0.0, 5.6 ± 0.2, 5.8 ± 0.2%), protein content in skeletal muscle of GLUT4 (1.5 ± 0.2, 0.9 ± 0.1, 1.0 ± 0.1 AU) and hexokinase II (1.6 ± 0.2, 1.0 ± 0.2, 0.7 ± 0.1 AU), citrate synthase activity (155 ± 6, 130 ± 5, 113 ± 5 μmol/g/min) and VO2max (49 ± 1, 43 ± 1, 41 ± 1 mL/min/FFM) (p < 0.05). Conclusion Cardiometabolic health is better in participants who have maintained >10% weight loss compared to moderate weight loss and weight regain.
AB - Objective Intensive lifestyle interventions (ILI) are criticised for ineffective obesity treatment because weight loss over time is modest and thus of limited clinical relevance. However, a subgroup (5–30%) maintains a clinical weight loss >10%, but it is not clear if cardiometabolic health follows this pattern. The aim was to study the effect of different magnitudes of weight loss maintenance after ILI on cardiometabolic health. Methods Eighty out of 2420 former participants (age: 36 ± 1, BMI: 38 ± 1, (means ±SE)) in an 11–12-week ILI were recruited into 3 groups; clinical weight loss maintenance (>10% weight loss), moderate maintenance (1–10%), and weight regain based on weight loss at follow-up (5.3 ± 0.4 years). Weight loss during the ILI was achieved by increased physical activity and hypo-caloric diet. Dual X-ray Absorptiometry, blood sample, skeletal muscle biopsy and VO2max test were used to determine cardiometabolic health at follow-up. Results At follow-up, the clinical weight loss maintenance group scored better in the following variables compared to the other groups: BMI (31 ± 1, 33 ± 2, 43 ± 2 kg/m2), composition (34 ± 2, 40 ± 1, 49 ± 1% fat), visceral adipose tissue (0.8 ± 0.2, 1.7 ± 0.5, 2.4 ± 0.4 kg), plasma triglycerides (0.8 ± 0.2, 1.3 ± 0.4, 1.6 ± 0.3 mmol/L), plasma glucose (4.9 ± 0.1, 5.9 ± 0.4, 5.9 ± 0.1 mmol/L), Hb1Ac (5.1 ± 0.0, 5.6 ± 0.2, 5.8 ± 0.2%), protein content in skeletal muscle of GLUT4 (1.5 ± 0.2, 0.9 ± 0.1, 1.0 ± 0.1 AU) and hexokinase II (1.6 ± 0.2, 1.0 ± 0.2, 0.7 ± 0.1 AU), citrate synthase activity (155 ± 6, 130 ± 5, 113 ± 5 μmol/g/min) and VO2max (49 ± 1, 43 ± 1, 41 ± 1 mL/min/FFM) (p < 0.05). Conclusion Cardiometabolic health is better in participants who have maintained >10% weight loss compared to moderate weight loss and weight regain.
U2 - 10.1016/j.orcp.2016.09.009
DO - 10.1016/j.orcp.2016.09.009
M3 - Journal article
C2 - 27720417
SN - 1871-403X
VL - 11
SP - 489
EP - 498
JO - Obesity Research & Clinical Practice
JF - Obesity Research & Clinical Practice
IS - 4
ER -